Table 2.
Analysis of immune escape-associated mutations in the major hydrophilic region in patients with and without resistance mutations
| Clinical features | Resistance mutation (+), n = 6982 | Resistance mutation (-), n = 12458 | P value | The MHR Mutation occurrence [(+) vs (-)] |
| Age in year | 44.01 ± 11.73 | 39.01 ± 13.08 | < 0.05 | |
| Gender, male | 5709 (81.77%) | 9982 (80.13%) | < 0.05 | |
| HBV genotype, C%/B% | 86.79/12.52 | 83.00/16.05 | < 0.05 | |
| HBV DNA as log10 IU/mL | 4.62 (3.17, 6.47) | 4.24 (2.83, 6.16) | < 0.05 | |
| sY100S | 20 (0.29%) | 29 (0.23%) | NS | |
| sQ101H/K/R | 298 (4.27%) | 229 (1.84%) | < 0.05 | ↑ |
| sM103I/T | 8 (0.11%) | 14 (0.11%) | NS | |
| sL109I/P/R | 12 (0.17%) | 24 (0.19%) | NS | |
| sP111L/Q/S | 10 (0.14%) | 21 (0.17%) | NS | |
| sG112K/R | 4 (0.06%) | 9 (0.07%) | NS | |
| sS114A/L/T | 117 (1.68%) | 137 (1.10%) | < 0.05 | ↑ |
| sT115A/N | 2 (0.03%) | 8 (0.06%) | NS | |
| sT116N | 6 (0.09%) | 32 (0.26%) | < 0.05 | ↑ |
| sS117G/N/R | 5 (0.07%) | 19 (0.15%) | NS | |
| sT118A/K/M/R/S/V | 31 (0.44%) | 32 (0.26%) | < 0.05 | ↑ |
| sG119E/R/T | 6 (0.09%) | 10 (0.08%) | NS | |
| sP120A/L/Q/S/T | 107 (1.53%) | 35 (0.28%) | < 0.05 | ↑ |
| sC121R/S | 1 (0.01%) | 1 (0.01%) | NS | |
| sK122R | 154 (2.21%) | 315 (2.53%) | NS | |
| sT123A/I/N/S/V | 56 (0.80%) | 91 (0.73%) | NS | |
| sC124R/Y | 4 (0.06%) | 9 (0.07%) | NS | |
| sT125A/M | 8 (0.11%) | 21 (0.17%) | NS | |
| sT/I126A/N/P/S | 366 (5.24%) | 534 (4.29%) | < 0.05 | ↑ |
| sP127H/L/S/T | 91 (1.30%) | 165 (1.32%) | NS | |
| sA128T/V | 7 (0.10%) | 15 (0.12%) | NS | |
| sQ129N/H/P/R | 90 (1.29%) | 129 (1.04%) | NS | |
| sG130A/K/N/R/S | 65 (0.93%) | 85 (0.68%) | NS | |
| sT131A/I/K/N | 133 (1.90%) | 219 (1.76%) | NS | |
| sS132F/P | 2 (0.03%) | 9 (0.07%) | NS | |
| sM133I/L/T | 196 (2.81%) | 277 (2.22%) | < 0.05 | ↑ |
| sF/Y134H/L/R/S/V | 65 (0.93%) | 51 (0.41%) | NS | |
| sS136F/P/Y | 6 (0.09%) | 4 (0.03%) | NS | |
| sC137W/Y | 9 (0.13%) | 5 (0.04%) | < 0.05 | ↑ |
| sC139R/S/Y | 3 (0.04%) | 9 (0.07%) | NS | |
| sT140I | 39 (0.56%) | 61 (0.49%) | NS | |
| sK141E/R | 3 (0.04%) | 4 (0.03%) | NS | |
| sP142L | 11 (0.16%) | 9 (0.07%) | NS | |
| sD144A/E | 17 (0.24%) | 26 (0.21%) | NS | |
| sG145A/R | 123 (1.76%) | 163 (1.31%) | < 0.05 | ↑ |
| sC147R/Y | 0 | 0 | NS | |
| sS154P | 1 (0.01%) | 2 (0.02%) | NS | |
| sA159G/V | 223 (3.19%) | 319 (2.56%) | < 0.05 | ↑ |
| sV168A | 143 (2.05%) | 234 (1.88%) | NS | |
| Average number/patient | 0.35 | 0.27 | < 0.05 | ↑ |
| Patient percentage with the MHR mutation(s) | 23.32% (1628/ 6982) | 18.51% (2306/12458) | < 0.05 | ↑ |
(+): Positive; (-): Negative; DNA: Deoxyribonucleic acid; HBV: Hepatitis B virus; MHR: Major hydrophilic region; NS: Not significant.